Bruce McCall

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek et al. · Journal for ImmunoTherapy of Cancer · 2018 · 152 citations · Full text

Medicine, Oncology, Pharmacology +9

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette, Lori J. Wirth, Cristina Oprean et al. · Frontiers in Oncology · 2016 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

Jeffrey R. Infante, Aaron R. Hansen, Michael J. Pishvaian et al. · Journal of Clinical Oncology · 2016 · 78 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Lihua E. Budde, Laurie H. Sehn, Sarit Assouline et al. · Blood · 2018 · 59 citations

Medicine, Immunology, Oncology +17

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

Andrew Hill, Michael Findlay, Matthew Burge et al. · Clinical Cancer Research · 2018 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17